Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Lyell Immunopharma (Nasdaq:LYEL) filed an 8-K (Item 3.02) disclosing that the clinical milestone embedded in its October 2024 ImmPACT Bio merger has been met. The achievement obligates Lyell to issue 625,000 unregistered common shares (post 1-for-20 reverse split) to former ImmPACT securityholders in a private placement relying on the Section 4(a)(2) exemption.
The shares represent additional equity consideration; no cash will be paid. While the filing does not quantify the percentage of outstanding stock, the issuance will incrementally dilute current holders. The milestone confirms progress for ImmPACT’s next-generation CAR T-cell candidate, potentially accelerating Lyell’s cell-therapy pipeline.
- Shares are restricted and cannot be publicly resold without registration or another exemption.
- No other material items were reported.